Search
Piboserod
go.drugbank.com/drugs/DB04873InvestigationalPiboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.
Methacholine
go.drugbank.com/drugs/DB06709ApprovedAsthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing sympt...
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalINCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. ...
Stamulumab
go.drugbank.com/drugs/DB05915InvestigationalMYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Beclamide
go.drugbank.com/drugs/DB09011ExperimentalBeclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity. It was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures.
Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicit[A177754] Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] One disadvantage of this approach is the possible development of antibodies (inhibitors) towards the administered replacement factor, rendering them less effective and increasing the likelihood
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigational[L43882] A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the … of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.